ClinicalTrials.gg
RecruitingNCT07575191Updated Jun 12, 2026

Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer

A Phase 1/2 interventional study of Gemcitabine and Extroducer Infusion Catheter System in Pancreatic Cancer Non-resectable, sponsored by Smartwise Sweden AB. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Smartwise Sweden AB · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 369 studies testing gemcitabine in Pancreatic Neoplasms — 29 open to participants now, 44 under way, 5 of them phase 3. Gemcitabine · Pancreatic Neoplasms.

Planned enrollment
294th of 352
9 · median 37
Started
2026
with 5 others
Phase 1/2
38 of 369
3 open now
Primary completion
2027-12
later than 36 of 43 live
Registered
367th of 369
by date

Among the 369 studies testing gemcitabine in Pancreatic Neoplasms, this one is the 294th largest by planned enrollment of the 352 interventional ones that give a count, is one of 6 that started in 2026, is one of 38 in phase 1/2, reaches primary completion later than 36 of the 43 other live ones, and was the 367th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

29 of the 369 studies testing gemcitabine in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

23 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 745 Pancreatic Neoplasms studies recruiting now, 478 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies testing gemcitabine in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

This study is testing a new way to deliver the chemotherapy drug Gemcitabine in pancreatic tumors using the catheter Extroducer® Infusion Catheter System. The study will include patients with Locally Advanced Pancreatic Cancer that cannot be removed with surgery.

Patients will receive four treatment sessions, given every two weeks, in which Gemcitabine is infused directly into or near the tumor. The study will test up to three increasing dose levels of Gemcitabine (200 mg, 400 mg, and 100 mg).

The study will enroll three groups of three patients each. After each group completes treatment, an independent safety committee will review the results to decide whether it is safe to move to the next dose per predefined study criteria.

After finishing treatment, patients will be followed for six months. Each patient's total participation in the study will last about 8-9 months. The main goal of the study is to evaluate the safety and feasibility of this treatment approach.

Read the detailed description

This is a prospective, interventional, non-randomized, open-label pilot study designed to evaluate the safety and performance of the Extroducer® Infusion Catheter System for peri- and intratumoral delivery of Gemcitabine in patients with unresectable Locally Advanced Pancreatic Cancer (LAPC).

The study uses a dose-escalation design with three sequential cohorts to assess the feasibility and safety of repeated peri-/intratumoral Gemcitabine infusions at dose levels of 100 mg, 200 mg, and 400 mg.

Each patient is planned to receive four study treatment sessions administered every two weeks. Following completion of the treatment phase, patients will be followed for 6 months until study completion. The total study participation per patient is expected to be approximately 8-9 months.

Each cohort will include three patients. After completion of study treatment by all patients in a cohort, the Data Safety Monitoring Board (DSMB) will review safety data and determine whether dose escalation is appropriate based on the occurrence of study-defined dose-limiting toxicities (DLTs), and will recommend the dose level for the next cohort.

A total of nine eligible participants are planned to be enrolled at one study site in Sweden.

03

Conditions studied

  • Pancreatic Cancer Non-resectable
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to comply with scheduled visits, treatment plan, able to undergo catheterization, imaging procedures, laboratory tests, required follow up visits, the filling out of required forms, and have the ability to understand and give written .
  • Voluntarily agrees to participate and has duly singed the Informed Consent Form.
  • Age 18 years or older.
  • confirmed, locally advanced pancreatic cancer.
  • Systemic treatment with IV chemotherapy for at least six months.
  • (ECOG) performance status of 0 or 1.
  • The target tumor is a measurable tumor according to the (RECIST) criteria v1.1 prior to initiating Extroducer® Gemcitabine treatment.
  • Stable disease or locally progressive disease without signs of disease as evaluated at a multidisciplinary tumor board within 4 weeks prior to first dose.
  • Locally Advanced Pancreatic Cancer not amenable to resection as evaluated at a multidisciplinary tumor board within 4 weeks prior to first dose.
  • Have acceptable organ and marrow function as defined below:

    i. (ANC) ≥ 1500 cells/mm³ (1.5x109 cells/L) ii. ≥ 9.0 g/dL iii. ≥ 100,000/µL iv. Total ≤ 2 × (ULN). v. (Aspartate Aminotransferase) ≤ 3 × ULN. vi. ALT (Alanine Aminotransferase) ≤ 3 × ULN vii. Creatinine Within 1.5 x ULN OR ≥ 60 mL/min for patients with creatinine levels above 1.5 x ULN.

  • Women of (defined as all women who are not surgically sterile or for at least 1 year prior to enrollment) must have a negative urine pregnancy test at enrollment and must agree to use a medically acceptable and highly effective from enrollment until 6 months after final study treatment of Gemcitabine.
  • Male subjects who are planning to father a child (i.e., planning a pregnancy with a partner) during the clinical investigation.

    i. Male subjects must agree to use highly effective contraception with female partners of childbearing potential during the clinical investigation and for 3 months after the last dose of Gemcitabine and must not donate sperm during this period.

ii. Acceptable methods include: a condom in addition to combined hormonal contraception, progestogen-only contraception, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion in the female partner, or vasectomy of the male participant (confirmed azoospermia).

iii. Sexual abstinence is acceptable only if it is the subject's usual and preferred lifestyle; periodic abstinence and withdrawal are not acceptable.

Exclusion criteria

Exclusion Criteria:

  • Participating in another clinical investigation which may interfere with the results in this clinical investigation per investigator judgement.
  • Inability to consent.
  • Pancreatic tumor is different from adenocarcinoma (e.g., neuroendocrine, ). Adenosquamous is allowed.
  • Cancer has spread to other organs or non-regional lymph nodes (Metastases).
  • Unknown stage or recurrent pancreatic cancer.
  • Patient to Gemcitabine treatments.
  • Patients in which iodine contrast is contraindicated.
  • Presence of structures that impede tumor access.
  • Concurrent or prior unless disease-free for ≥3 years, with exceptions for nonmelanoma skin cancer, carcinoma in situ of the cervix or bladder, or Gleason Grade \< 7 organ-confined prostate cancer. This may be subject to investigator's judgement based on individual patient circumstances and the nature of the malignancy.
  • Unmanaged concurrent illnesses, encompassing psychiatric conditions or challenging social circumstances, that, as per the investigator's judgment, could undermine compliance to the study protocols or pose an unacceptable risk to the patient.
  • Pregnant or nursing individuals.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    Sequential targeted Gemcitabine delivery

    Participants receive Gemcitabine administered via the Extroducer® Infusion Catheter System for targeted intra-arterial delivery, according to a predefined sequential treatment protocol.

    Drug: Gemcitabine · Device: Extroducer Infusion Catheter System

Interventions

  • Gemcitabine administered via the Extroducer Infusion Catheter System for targeted delivery.

  • DeviceExtroducer Infusion Catheter System

    Infusion catheter system for delivery of diagnostic or therapeutic agents into the extravascular space or peripheral vasculature.

06

What researchers measure

Primary outcomes

  1. Extroducer® related Serious Adverse Events

    Occurrence of Extroducer® related Serious Adverse Events within 72 hours post Extroducer® treatment infusion with Gemcitabine.

    Time frame: From each study treatment until 72 hours post treatment.

Secondary outcomes

  1. Gemcitabine related Serious Adverse Events

    Occurrence of Gemcitabine related Serious Adverse Events from first Extroducer® treatment infusion with Gemcitabine until study completion.

    Time frame: From first study treatment on Day 0 until study completion, ~8 Months.

  2. Overall Survival

    Overall Survival (OS) at 6 months after final Extroducer® treatment infusion with Gemcitabine.

    Time frame: Through study completion, ~8 Months.

  3. Progression Free Survival

    Progression Free Survival (PFS) at 6 months after final Extroducer® treatment infusion with Gemcitabine.

    Time frame: Through study completion, ~8 Months.

  4. Tumor resectability

    Classification of tumor resectability according to NCCN resectability criteria before (baseline) and after (Visits 11-13) Extroducer® treatment infusion with Gemcitabine.

    Time frame: Through study completion, ~8 Months.

  5. Tumor response

    Classification of tumor response according to RECIST before (baseline) and after (Visits 11-13) Extroducer® treatment infusion with Gemcitabine.

    Time frame: Through study completion, ~8 Months.

  6. Tumor marker

    Evaluation of the tumor marker CA-19-9 before (baseline) and after (Visits 9, 11-13) Extroducer® treatment infusion with Gemcitabine.

    Time frame: Through study completion, ~8 Months.

  7. Patient Quality of Life

    Evaluation of subjects' quality of life using the EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 items) and EORTC PAN26 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Pancreatic Cancer Module 26) questionnaires before (baseline) and after (Visits 11-13) Extroducer® treatment infusion with Gemcitabine. All scales and single-item measures are scored from 1 to 100. Higher scores indicate a higher level of the measured construct. For functional scales, a higher score represents better or healthier functioning. A higher score on the Global Health Status/Quality of Life scale indicates better quality of life, whereas a higher score on symptom scales or items reflects a greater level of symptoms or problems. The two questionnaires are intended to be used together as a single module and therefore constitute one combined outcome measure.

    Time frame: Through study completion, ~8 Months.

  8. Incidence of Adverse Events and Device Deficiencies

    The incidence, severity, and seriousness of Adverse Events and Device Deficiencies throughout the clinical investigation.

    Time frame: Through study completion, ~8 Months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Individual participant data (IPD) are not planned to be shared. Study results will be reported in aggregate form through peer-reviewed publications.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

Of 115 industry-sponsored phase 1/2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 88. This study's planned 20 months is below that.

Counting every sponsor, half of 209 studies reached it within 51 months; a quarter within 36 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2026
First posted
May 8, 2026
StartActual
Apr 29, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Jun 2028
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07575191
Lead sponsor
Smartwise Sweden AB
Responsible party
Sponsor
First posted
May 8, 2026
Start date
Apr 29, 2026
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jun 12, 2026

Study contacts

Ulrik Birgersson, PhD, MSc
Contact
Ulrik.Birgersson@smartcella.com
+46 70 842 10 54

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemcitabine

Start the discussion